Lasa Supergenerics board approved the appointment of Mr. Janardan Savala as Whole-time Director and Executive Director for a five-year term starting August 26, 2026.

The board also approved the re-appointment of Chairman and Managing Director Dr. Omkar Pravin Herlekar, who retires by rotation. The company scheduled its 11th Annual General Meeting (AGM) for September 30, 2026, to be conducted via video conferencing.

Key Board Approvals

The board meeting held on September 9, 2026, covered several governance and operational matters:

• Director Appointments: Approval of Mr. Janardan Savala’s appointment as Executive Director and re-appointment of Dr. Omkar Herlekar.
• AGM Logistics: The 11th AGM is scheduled for September 30, 2026, at 9:30 am through Video Conferencing/Other Audio-Visual Means (OAVM).
• Auditor Appointment: Shareholder consent sought for appointing Mr. Shivam Sharma of Ms. Shivam Sharma & Associates as Secretarial Auditor for five years (FY26 to FY30).

Governance and Financial Powers

The AGM notice includes special resolutions for shareholder approval on critical corporate powers:

• Donations: Authorization to donate up to ₹2 crore per annum to charitable trusts, including the Dr. Omkar Herlekar Foundation, even if it exceeds 5% of average net profits.
• Managerial Remuneration: Approval to pay total managerial remuneration up to ₹3 crore per annum in cases of inadequate or no profits.
• Borrowing Powers: Consent for the board to borrow secured or unsecured funds exceeding paid-up capital and free reserves. Funds are intended for repaying disputed external borrowing loans or other approved purposes.

What the Numbers Show

The approval of borrowing powers specifically mentions utilizing funds for the "repayment of alleged External Borrowing Loan which is disputed at present." This indicates a targeted use of capital to resolve specific liability issues rather than general working capital expansion, highlighting a focused approach to balance sheet cleanup alongside routine governance renewals.

Lasa Supergenerics appointed Janardan Kamlu Savala as an additional executive director on August 26, 2026. The board approved the appointment during its meeting held that day. Shareholder approval is required for the position to become permanent.

The company disclosed the outcome pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board meeting commenced at 11:00 am and concluded at 1:00 pm.

Appointment Details

Savala will serve as an occupier of all units of the company. His term runs from August 26, 2026, to August 25, 2031. The appointment remains subject to ratification by members at the ensuing general meeting or via postal ballot.

Profile and Expertise

Savala, born on May 15, 1994, holds an undergraduate degree. He brings experience in business operations and commercial practices. His expertise includes coordination with financial institutions and handling banking formalities. He facilitates documentation and compliance-related interactions.

He currently holds no directorships in other public companies. He also holds no memberships or chairmanships in audit or stakeholders' relationships committees across public companies. Savala does not hold any shares in Lasa Supergenerics.